1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654.
2. National Cancer Institute. Lung and bronchus cancer. Long-term trends in SEER age-adjusted incidence rates, 1975–2017. By sex, all races (includes Hispanic), all ages, delay-adjusted rates. SEER*Explorer. https://seer.cancer.gov/explorer/application.html?site=47&data_type=1&graph_type=1&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&hdn_stage=101&rate_type=2&advopt_precision=1&advopt_display=2. Accessed 27 Nov 2020.
3. National Cancer Institute. Lung and bronchus cancer. Stage distribution of SEER incidence cases, 2008–2017. By sex, all races (includes Hispanic), all ages. SEER*Explorer. https://seer.cancer.gov/explorer/application.html?site=47&data_type=1&graph_type=4&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1&advopt_display=2. Accessed 27 Nov 2020.
4. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up (2020 update). https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer. Accessed Apr 2021.
5. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985–93. https://doi.org/10.18632/oncotarget.12587.